Multiple myeloma (MM) is an incurable progressive disease. Many therapeutic options are available to delay progression, including autologous and allogeneic bone marrow transplantation. At advanced stages, MM is often refractory to treatment. We report a heavily pretreated patient with graft-versus-host disease after bone marrow transplantations, treated at a terminal stage with a modified protocol for arsenic trioxide (ATO). This patient with poor clinical status tolerated the treatment very well. He had a remarkable clinical response and achieved complete remission. The mechanisms of ATO are presented and the potential role of ATO for MM is discussed.

Keywords:
Arsenic trioxide, Bone marrow transplantation, Graft-versus-host disease, Multiple myeloma
1.
Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 2004;351:1860–1873.
2.
Harousseau JL, Shaughnessy J Jr, Richardson P: Multiple myeloma. Hematology Am Soc Hematol Educ Program 2004;237–256.
3.
Antman KH: Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6(suppl 2):1–2.
4.
Waxman S, Anderson KC: History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6(suppl 2):3–10.
5.
Zhu J, Chen Z, Lallemand-Breitenbach V, de The H: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705–713.
6.
Rojewski MT, Korper S, Schrezenmeier H: Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004;45:2387–2401.
7.
Bachleitner-Hofmann T, Kees M, Gisslinger H: Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma 2002;43:1535–1540.
8.
Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ: Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002;39(suppl 1):22–26.
9.
Langston AA, Walling R, Winton EF: Update on myelodysplastic syndromes: new approaches to classification and therapy. Semin Oncol 2004;31(suppl 4):72–79.
10.
List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P: Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17:1499–1507.
12.
Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851–860.
13.
Barbey JT, Pezzullo JC, Soignet SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609–3615.
14.
Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R: Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125:470–476.
15.
Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002;16:1835–1837.
16.
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658–3668.
17.
Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805–813.
18.
Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhao RC: Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 2004;53:51–60.
19.
Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G: An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988;158:1065–1070.
20.
Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl 2):S133–S144.
21.
Caillot D, Casasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H: Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161–169.
22.
Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535–541 (comment published in J Antimicrob Chemother 1993;31:806–808).
23.
Janoff AS, Perkins WR, Saletan SL, Swenson CE: Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451–472.
24.
Kalmadi SR, Hussein MA: The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 2006;116:1–7.
25.
Munshi NC: Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001;6(suppl 2):17–21.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.